MX2012007320A - Formulacion que comprende antagonistas ampa de 1h-quinazolina-2, 4-diona, en la forma de tabletas de liberacion inmediata y su preparacion. - Google Patents
Formulacion que comprende antagonistas ampa de 1h-quinazolina-2, 4-diona, en la forma de tabletas de liberacion inmediata y su preparacion.Info
- Publication number
- MX2012007320A MX2012007320A MX2012007320A MX2012007320A MX2012007320A MX 2012007320 A MX2012007320 A MX 2012007320A MX 2012007320 A MX2012007320 A MX 2012007320A MX 2012007320 A MX2012007320 A MX 2012007320A MX 2012007320 A MX2012007320 A MX 2012007320A
- Authority
- MX
- Mexico
- Prior art keywords
- substituents
- amino
- alkoxycarbonyloxy
- alkoxycarbonylamino
- dialkylamino
- Prior art date
Links
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 title 1
- 229940098747 AMPA receptor antagonist Drugs 0.000 title 1
- 239000000775 AMPA receptor antagonist Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 4
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 abstract 4
- 125000003282 alkyl amino group Chemical group 0.000 abstract 4
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- -1 cyano, hydroxy Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000004442 acylamino group Chemical group 0.000 abstract 2
- 125000004423 acyloxy group Chemical group 0.000 abstract 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención proporciona una tableta que comprende una hidroxi-propil-celulosa y un ingrediente activo seleccionado a partir de los compuestos de la fórmula (I), y sales de los mismos: (Ver Formula) en donde: R1 representa CF3, CHF2, CH2F, CH3CHF-, CH3CF2-, etilo, o iso-propilo, y R2 representa alquilo sustituido por uno o más sustituyentes, siendo los sustituyentes seleccionados a partir del grupo que consiste en halógeno, nitro, ciano, acilo, hidroxilo, oxo (=O), alcoxilo, cicloalcoxilo, aciloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquil-amino, formilo, acil-amino, alcoxi-carbonil-amino, o R2 representa heterociclil-alquilo sustituido por uno o más sustituyentes, siendo los sustituyentes seleccionados a partir del grupo que consiste en halógeno, nitro, ciano, hidroxilo, alcoxilo, alquil-carboniloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquil-amino, alcoxi-carbonil-amino, o R2 representa fenilo sustituido por uno o más sustituyentes, siendo los sustituyentes seleccionados a partir del grupo que consiste en ciano, hidroxilo, alcandiilo, alquendiilo, alcoxilo, hidroxialquilo, formilo, alquil-carbonilo, alcoxi-carbonilo, alquil-carboniloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquilamino, amino-alquilo, alquil-amino-alquilo, dialquil-amino-alquilo, alcoxi-carbonil-amino, o R2 representa heterociclilo opcionalmente sustituido por uno o más sustituyentes, siendo los sustituyentes seleccionados a partir del grupo que consiste en halógeno, hidroxilo, amino, nitro, ciano, alquilo, hidroxi-alquilo, alcoxi-alquilo, amino-alquilo, alquil-amino alquilo, dialquil-amino-alquilo, acilo, alcoxilo, aciloxilo, alcoxi-carboniloxilo, amino, alquil-amino, dialquil-amino, acil-amino, alcoxi-carbonil-amino, y en donde el heterociclo se enlaza al anillo de fenilo mediante un átomo de carbono. La invención también proporciona un proceso para la preparación de la tableta anterior.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28898509P | 2009-12-22 | 2009-12-22 | |
| PCT/US2010/061553 WO2011079119A1 (en) | 2009-12-22 | 2010-12-21 | Formulation comprising 1 h - quinazoline - 2, 4 - dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012007320A true MX2012007320A (es) | 2012-07-20 |
Family
ID=43610748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012007320A MX2012007320A (es) | 2009-12-22 | 2010-12-21 | Formulacion que comprende antagonistas ampa de 1h-quinazolina-2, 4-diona, en la forma de tabletas de liberacion inmediata y su preparacion. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20120263791A1 (es) |
| EP (1) | EP2515873A1 (es) |
| JP (1) | JP2013515076A (es) |
| KR (1) | KR20120105035A (es) |
| CN (2) | CN104013587A (es) |
| AU (1) | AU2010336510B2 (es) |
| BR (1) | BR112012016920A2 (es) |
| CA (1) | CA2784996A1 (es) |
| CL (1) | CL2012001689A1 (es) |
| EC (1) | ECSP12011994A (es) |
| GT (1) | GT201200209A (es) |
| MA (1) | MA33834B1 (es) |
| MX (1) | MX2012007320A (es) |
| NZ (1) | NZ600717A (es) |
| PE (1) | PE20121394A1 (es) |
| PH (1) | PH12012501289A1 (es) |
| RU (1) | RU2012131051A (es) |
| SG (1) | SG181787A1 (es) |
| WO (1) | WO2011079119A1 (es) |
| ZA (1) | ZA201204607B (es) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2465693A1 (en) * | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| GB0416730D0 (en) * | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| WO2006110811A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
| JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
| EP1968553A2 (en) * | 2005-11-09 | 2008-09-17 | Novartis AG | Process for making pharmaceutical compositions with a transient plasticizer |
| US8673353B2 (en) * | 2008-02-11 | 2014-03-18 | Dainippon Sumitomo Pharma Co., Ltd | Tablet having improved elution properties |
-
2010
- 2010-12-21 MX MX2012007320A patent/MX2012007320A/es not_active Application Discontinuation
- 2010-12-21 CN CN201310590709.7A patent/CN104013587A/zh active Pending
- 2010-12-21 PE PE2012000861A patent/PE20121394A1/es not_active Application Discontinuation
- 2010-12-21 JP JP2012546151A patent/JP2013515076A/ja active Pending
- 2010-12-21 NZ NZ600717A patent/NZ600717A/en not_active IP Right Cessation
- 2010-12-21 RU RU2012131051/15A patent/RU2012131051A/ru not_active Application Discontinuation
- 2010-12-21 US US13/518,027 patent/US20120263791A1/en not_active Abandoned
- 2010-12-21 AU AU2010336510A patent/AU2010336510B2/en not_active Expired - Fee Related
- 2010-12-21 CA CA2784996A patent/CA2784996A1/en not_active Abandoned
- 2010-12-21 KR KR1020127019189A patent/KR20120105035A/ko not_active Withdrawn
- 2010-12-21 CN CN2010800643985A patent/CN102770124A/zh active Pending
- 2010-12-21 PH PH1/2012/501289A patent/PH12012501289A1/en unknown
- 2010-12-21 EP EP10803319A patent/EP2515873A1/en not_active Withdrawn
- 2010-12-21 WO PCT/US2010/061553 patent/WO2011079119A1/en not_active Ceased
- 2010-12-21 SG SG2012044905A patent/SG181787A1/en unknown
- 2010-12-21 BR BR112012016920A patent/BR112012016920A2/pt not_active IP Right Cessation
-
2012
- 2012-06-18 MA MA34983A patent/MA33834B1/fr unknown
- 2012-06-21 ZA ZA2012/04607A patent/ZA201204607B/en unknown
- 2012-06-21 EC ECSP12011994 patent/ECSP12011994A/es unknown
- 2012-06-21 CL CL2012001689A patent/CL2012001689A1/es unknown
- 2012-06-22 GT GT201200209A patent/GT201200209A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2784996A1 (en) | 2011-06-30 |
| EP2515873A1 (en) | 2012-10-31 |
| MA33834B1 (fr) | 2012-12-03 |
| BR112012016920A2 (pt) | 2016-04-12 |
| ECSP12011994A (es) | 2012-07-31 |
| SG181787A1 (en) | 2012-07-30 |
| GT201200209A (es) | 2013-09-09 |
| AU2010336510B2 (en) | 2014-06-26 |
| WO2011079119A1 (en) | 2011-06-30 |
| RU2012131051A (ru) | 2014-01-27 |
| CN104013587A (zh) | 2014-09-03 |
| KR20120105035A (ko) | 2012-09-24 |
| PH12012501289A1 (en) | 2013-01-07 |
| PE20121394A1 (es) | 2012-10-29 |
| JP2013515076A (ja) | 2013-05-02 |
| AU2010336510A1 (en) | 2012-07-12 |
| CN102770124A (zh) | 2012-11-07 |
| NZ600717A (en) | 2014-06-27 |
| ZA201204607B (en) | 2013-02-27 |
| US20120263791A1 (en) | 2012-10-18 |
| CL2012001689A1 (es) | 2013-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP201706620B (en) | NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS | |
| PE20141582A1 (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
| MA37405A1 (fr) | Composés hétérocyclyle | |
| GEP20135992B (en) | Sulfonamide derivatives | |
| SI2751083T1 (en) | Quinolone compound | |
| PE20141408A1 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| EA201170769A1 (ru) | Органические соединения | |
| PE20141540A1 (es) | Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 | |
| MX2014013957A (es) | Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia). | |
| MX2021002256A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| MX347619B (es) | Polimorfos y sales de 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-p iperazinil] metil}-1,3-oxazol-2-il)-1h-indazol como inhibidores de pi3k para usarse por ejemplo en el tratamiento de trastornos respiratorios. | |
| NZ602954A (en) | Inhibitors of protein tyrosine kinase activity | |
| EA201200903A1 (ru) | Гербицидно активные заместители 2-(замещенного-фенила)циклопентан-1,3-диона | |
| PE20142421A1 (es) | Fenilimidazopirazoles sustituidos y su uso | |
| PE20140629A1 (es) | Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos | |
| MX343165B (es) | Agonistas del receptor 5-ht4 para el tratamiento de demencia. | |
| ZA202005507B (en) | 10-(di(phenyl)methyl)-4-hydroxy-8,9,9a,10-tetrahydro-7h-pyrrolo[1 ',2':4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza | |
| PH12020552236A1 (en) | Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof | |
| MX2012007320A (es) | Formulacion que comprende antagonistas ampa de 1h-quinazolina-2, 4-diona, en la forma de tabletas de liberacion inmediata y su preparacion. | |
| TN2012000310A1 (en) | Formulation comprising 1 h - quinazoline - 2, 4 - dione ampa receptor antagonists, in the form of immediate release tablets and preparation thereof | |
| MX2010007350A (es) | Derivados de 2-heteroaroil-imidazol[1,2-a]piridina, su preparacion y aplicacion terapeutica. | |
| TH131400A (th) | สูตรผสมที่ประกอบรวมด้วย 1h-ควินาโซลิน-2,4-ไดโอนแอมพารีเซปเตอร์แอนตะกอนิสต์ (1h-quinazoline-2,4-dione ampa receptor antagonists) ในรูปของยาเม็ดแบบปลดปล่อยทันที และการเตรียมสูตรผสมดังกล่าว | |
| MY170241A (en) | Novel pyridyl benzoxazine derivatives, pharmaceutical composition comprising the same, and use thereof | |
| MX2013002892A (es) | Derivados de dihidrobenzoxatiazepinas, preparacion de los mismos, composiciones farmaceuticas y uso como moduladores del receptor ampa. | |
| UA103544C2 (uk) | Кристалічна форма і цинкової солі розувастатину |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |